Major Bleeding Events Are Stronger Predictors of Long-Term Mortality Than Coronary Events in Secondary Prevention Therapy for Ischaemic Heart Disease

Table 1

Baseline characteristics of the patients with ischaemic heart disease.

Patient characteristics		N = 1240
Age, years		77.3 ± 10.6
Male, n (%)		946 (76.3%)
BMI, kg/m^2		23.4 ± 3.2
Myocardial infarction, n (%)		491 (39.6%)
Angina pectoris, n (%)		709 (57.2%)
Vasospastic angina, n (%)		40 (3.2%)
Atrial fibrillation, n (%)		93 (7.5%)
Risk factors
Hypertension, n (%)		1085 (87.5%)
Diabetes mellitus, n (%)		413 (33.3%)
Dyslipidaemia, n (%)		935 (75.4%)
BP, mmHg	Systolic	126.6 ± 17.5
	Diastolic	69.5 ± 12.6
HbA1c in DM patients, %		6.7 ± 1.0
LDL-C, mg/dL		93.0 ± 28.5
Medication
Antiplatelet therapy, n (%)		1156 (93.2%)
Aspirin		89.7%
Thienopyridine		56.6%
Cilostazol		1.5%
Single		40.4%
Dual		52.3%
Triple		0.5%
Oral anticoagulation therapy, n (%)		103 (8.3%)
Statin, n (%)		939 (75.7%)
ACEI and ARB, n (%)		755 (60.9%)
Beta-blocker, n (%)		299 (24.1%)
CCB, n (%)		682 (55.0%)
Intervention
CABG, n (%)		161 (13.0%)
PCI, n (%)		880 (71.0%)

Values are presented as mean ± standard deviation unless otherwise indicated. BMI: body mass index; BP: blood pressure; HbA1c: glycated haemoglobin; LDL-C: low-density lipoprotein cholesterol; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; CABG: coronary artery bypass grafting; and PCI: percutaneous coronary intervention.